vs

Side-by-side financial comparison of Granite Ridge Resources, Inc. (GRNT) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $105.5M, roughly 2.0× Granite Ridge Resources, Inc.). On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -0.8%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 8.9%).

Granite Ridge Resources, Inc. is an independent upstream energy company focused on the exploration, development, and production of oil, natural gas, and natural gas liquids. It operates low-cost, high-yield onshore hydrocarbon assets across key U.S. basins, primarily serving North American energy markets.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

GRNT vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
2.0× larger
RARE
$207.3M
$105.5M
GRNT
Growing faster (revenue YoY)
RARE
RARE
+26.7% gap
RARE
25.9%
-0.8%
GRNT
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
8.9%
GRNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GRNT
GRNT
RARE
RARE
Revenue
$105.5M
$207.3M
Net Profit
$-128.6M
Gross Margin
Operating Margin
-34.5%
-54.7%
Net Margin
-62.0%
Revenue YoY
-0.8%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-0.19
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GRNT
GRNT
RARE
RARE
Q4 25
$105.5M
$207.3M
Q3 25
$112.7M
$159.9M
Q2 25
$109.2M
$166.5M
Q1 25
$122.9M
$139.3M
Q4 24
$106.3M
$164.6M
Q3 24
$94.1M
$139.5M
Q2 24
$90.7M
$147.0M
Q1 24
$89.0M
$108.8M
Net Profit
GRNT
GRNT
RARE
RARE
Q4 25
$-128.6M
Q3 25
$14.5M
$-180.4M
Q2 25
$25.1M
$-115.0M
Q1 25
$9.8M
$-151.1M
Q4 24
$-133.2M
Q3 24
$9.1M
$-133.5M
Q2 24
$5.1M
$-131.6M
Q1 24
$16.2M
$-170.7M
Operating Margin
GRNT
GRNT
RARE
RARE
Q4 25
-34.5%
-54.7%
Q3 25
17.4%
-106.9%
Q2 25
19.0%
-64.8%
Q1 25
34.6%
-102.6%
Q4 24
-6.5%
-74.3%
Q3 24
26.2%
-94.6%
Q2 24
24.1%
-79.1%
Q1 24
22.0%
-151.9%
Net Margin
GRNT
GRNT
RARE
RARE
Q4 25
-62.0%
Q3 25
12.9%
-112.8%
Q2 25
23.0%
-69.0%
Q1 25
8.0%
-108.5%
Q4 24
-80.9%
Q3 24
9.6%
-95.7%
Q2 24
5.6%
-89.5%
Q1 24
18.2%
-156.8%
EPS (diluted)
GRNT
GRNT
RARE
RARE
Q4 25
$-0.19
$-1.28
Q3 25
$0.11
$-1.81
Q2 25
$0.19
$-1.17
Q1 25
$0.07
$-1.57
Q4 24
$-0.09
$-1.34
Q3 24
$0.07
$-1.40
Q2 24
$0.04
$-1.52
Q1 24
$0.12
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GRNT
GRNT
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
$367.8M
Stockholders' EquityBook value
$605.8M
$-80.0M
Total Assets
$1.2B
$1.5B
Debt / EquityLower = less leverage
0.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GRNT
GRNT
RARE
RARE
Q4 25
$421.0M
Q3 25
$202.5M
Q2 25
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$150.6M
Q2 24
$480.7M
Q1 24
$112.3M
Total Debt
GRNT
GRNT
RARE
RARE
Q4 25
$367.8M
Q3 25
$300.0M
Q2 25
$275.0M
Q1 25
$250.0M
Q4 24
$205.0M
Q3 24
Q2 24
Q1 24
$137.5M
Stockholders' Equity
GRNT
GRNT
RARE
RARE
Q4 25
$605.8M
$-80.0M
Q3 25
$643.9M
$9.2M
Q2 25
$642.5M
$151.3M
Q1 25
$631.4M
$144.2M
Q4 24
$635.4M
$255.0M
Q3 24
$660.6M
$346.8M
Q2 24
$665.3M
$432.4M
Q1 24
$674.0M
$140.3M
Total Assets
GRNT
GRNT
RARE
RARE
Q4 25
$1.2B
$1.5B
Q3 25
$1.1B
$1.2B
Q2 25
$1.1B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.0B
$1.5B
Q3 24
$1.0B
$1.5B
Q2 24
$990.5M
$1.6B
Q1 24
$966.7M
$1.3B
Debt / Equity
GRNT
GRNT
RARE
RARE
Q4 25
0.61×
Q3 25
0.47×
Q2 25
0.43×
Q1 25
0.40×
Q4 24
0.32×
Q3 24
Q2 24
Q1 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GRNT
GRNT
RARE
RARE
Operating Cash FlowLast quarter
$64.5M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GRNT
GRNT
RARE
RARE
Q4 25
$64.5M
$-99.8M
Q3 25
$77.8M
$-91.4M
Q2 25
$78.0M
$-108.3M
Q1 25
$76.1M
$-166.5M
Q4 24
$68.2M
$-79.3M
Q3 24
$74.7M
$-67.0M
Q2 24
$64.2M
$-77.0M
Q1 24
$68.7M
$-190.7M
Free Cash Flow
GRNT
GRNT
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
GRNT
GRNT
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
GRNT
GRNT
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
GRNT
GRNT
RARE
RARE
Q4 25
Q3 25
5.36×
Q2 25
3.11×
Q1 25
7.75×
Q4 24
Q3 24
8.25×
Q2 24
12.58×
Q1 24
4.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GRNT
GRNT

Oil And Gas Service$87.6M83%
Natural Gas Storage$17.9M17%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons